Who We Are

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Our Pipeline

Our lead product, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01’s novel mechanism of action is designed to reestablish tear film homeostasis by activating natural tear film production.

Latest News

5/19/2020

Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

5/15/2020

Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock